Table 2. Primary antibodies used and pretreatment
| Marker |
Clone |
Antibody type |
Source |
Dilution |
Pretreatment |
|
| CA125 |
M11 |
M |
Fujirebio Diagnostics, Malvern, PA |
Prediluted |
No |
|
| EMA |
E29 |
M |
Dako Corporation, Carpinteria, CA |
1:800 |
No |
|
| Cytokeratin |
AE1/AE3 |
M |
Dako Corporation, Carpinteria, CA |
1:300 |
Trypsynization |
|
| CEA |
CEM010 |
M |
Mochida Pharmaceutical, Tokyo |
1:400 |
Trypsynization |
|
| Vimentin |
V9 |
M |
Dako Corporation, Carpinteria, CA |
1:1000 |
Autoclave |
|
| CD34 |
NU-4A1 |
M |
Nichirei Corporation, Tokyo |
1:50 |
No |
|
Antibody type M: monoclonal antibody.